A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Trial Profile

A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

Completed
Phase of Trial: Phase II/III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Fasinumab (Primary)
  • Indications Osteoarthritis; Pain
  • Focus Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 22 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 17 Oct 2016 According to a Regeneron Pharmaceuticals media release, the company is planning to advance only lower doses in phase 3 program, subject to discussion with FDA and other regulatory authorities.
    • 14 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top